The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Theranos Lab May Pose Jeopardy to Patient Health

Theranos Lab May Pose Jeopardy to Patient Health

February 1, 2016 • By Reuters Staff

  • Tweet
  • Email
Print-Friendly Version / Save PDF

(Reuters)—Deficient practices at a lab operated by blood-testing startup Theranos pose “immediate jeopardy to patient health and safety,” the U.S. government’s Centers for Medicare & Medicaid Services said in a letter to the company released on Wednesday.

You Might Also Like
  • Medical Lab Trade Group Sues Over U.S. Reimbursement Cuts
  • Is Your Office Lab Up to Par?
  • Greece’s Medicine Supply May Be in Jeopardy

Theranos, founded and led by Elizabeth Holmes, has been in the spotlight after reports in the Wall Street Journal suggested that the company’s blood-testing devices were flawed and had problems with accuracy.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

The CMS, in a letter to the company dated Jan. 25, told Theranos it had 10 days to provide evidence that it had corrected the issues causing concern.

Theranos, which is based on Palo Alto, Calif., said the CMS report did not reflect the current state of its lab in Newark, Calif.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

“We are still reviewing the report, but we addressed many of the observations during the survey and are actively continuing to take corrective action,” the company said. “A full plan of correction will be submitted to CMS within days.”

The company said the CMS’s findings did not apply to the whole lab and did not relate to the company’s lab in Arizona, where Theranos processes more than 90% of its tests.

Theranos, valued at about $9 billion, has promised to shake up medical testing by conducting a wide range of tests with just one drop of blood collected using a tiny vial, rather than the large vial typically used.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Filed Under: Drug Updates, Pharma Co. News Tagged With: Centers for Medicare and Medicaid Services (CMS), CMS, Legal, Safety, Theranos

You Might Also Like:
  • Medical Lab Trade Group Sues Over U.S. Reimbursement Cuts
  • Is Your Office Lab Up to Par?
  • Greece’s Medicine Supply May Be in Jeopardy
  • Clinical Laboratory Improvement Amendments Establish Quality Standards for Lab Tests

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)